SBC Medical Group Holdings Inc. (NASDAQ: SBC), a Japanese owner and operator of aesthetic medical clinics, has laid the groundwork for growth in 2026 following a year of significant expansion and strategic moves. The company, which operates 258 franchise locations as of September 30, 2025—a 15% year-over-year increase—has focused on making aesthetic medicine more accessible and differentiating itself through advanced treatments and competitive pricing.
In the third quarter of 2025, SBC reported a 5% sequential increase in average revenue per customer, reaching $298, and an 8.4% rise from Q1 2025. This improvement stems from a revised pricing strategy and a focus on higher-revenue customers through its multi-brand approach. The company also maintained a strong repeat rate of 72%. These results reflect the success of SBC's initiatives to enhance customer loyalty and boost per-visit spending.
Key highlights from 2025 include the launch of new brands such as "Neo Skin Clinic" and "Hada no Aozora Clinic" in Tokyo, the latter integrating insurance-covered general dermatology with private-pay aesthetic treatments. SBC also expanded internationally into Singapore and Thailand, and in early 2026, announced its first U.S. expansion. The company acquired MB Career Lounge Co. Ltd., a provider of management support services for medical institutions, and integrated a related subsidiary, Waqoo, to accelerate R&D in clinical areas like AGA and orthopedics.
SBC Medical's inclusion in the Russell 3000 Index in 2025 increased its visibility among institutional and individual investors, potentially broadening its shareholder base. The company also initiated a stock buyback program of up to $5 million, signaling confidence in its growth prospects despite perceived undervaluation.
Capitalizing on cosmetic tourism, SBC is actively targeting Chinese consumers visiting Japan for procedures, enhancing its Chinese-language services and marketing on Chinese social media platforms. In Singapore, the company expanded its collaboration with Aesthetic Healthcare Holdings Pte. Ltd., acquired in 2024. In Thailand, SBC signed an e-consulting agreement with BLEZ ASIA Co. Ltd., which operates over 20 pharmacies and clinics, to support a new dermatology-focused clinic in Bangkok.
The global cosmetic surgery and procedure market, valued at $122.08 billion in 2022, is expected to grow at a CAGR of 14.7% from 2023 to 2030, according to industry reports. SBC Medical's strategic positioning—bolstered by a strong cash position of $125 million at the start of 2025, clinic expansions, and international entries—positions it to capture a larger share of this growing market.
For more details on SBC Medical's growth strategy, click here.
